C$1.33 -0.1 -4.3%
Last Trade - 14/04/21
| Market Cap | £47.4m |
| Enterprise Value | £49.0m |
| Revenue | £22.2k |
| Position in Universe | 938th / 2712 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Sep | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.038 | 0.000 | 0.000 | 0.000 | 0.094 | 0.068 | +12.5% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies that make a medical or commercial impact. Its technology platforms include AB569, MetaBlok, Arch Inflammation, Borg and MetaMx. AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. MetaBlok is a drug candidate targeting sepsis, cancer metastasis and inflammation based diseases. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. Arch Inflammation is focused on developing anti-inflammatory small molecules that target proteins in the innate immune system. Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation. MetaMx are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The Company has not generated any revenues.
| Last Annual | September 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | November 13, 2003 |
| Public Since | October 9, 1996 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | TSX Venture Exchange |
| Shares in Issue | 61,462,302 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 545 King St W, TORONTO, M5V 1M1, Canada |
| Web | http://archbiopartners.com/ |
| Phone | +1 647 4287031 |
| Contact | () |
| Auditors | Baker Tilly HMA LLP |
As of 14/04/21, shares in Arch Biopartners Inc are trading at C$1.33, giving the company a market capitalisation of £47.4m. This share price information is delayed by 15 minutes.
Shares in Arch Biopartners Inc are currently trading at C$1.33 and the price has moved by 50.55% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arch Biopartners Inc price has moved by 9.43% over the past year.
There are no analysts currently covering Arch Biopartners Inc.
Arch Biopartners Inc is scheduled to issue upcoming financial results on the following dates:
Arch Biopartners Inc does not currently pay a dividend.
Arch Biopartners Inc does not currently pay a dividend.
Arch Biopartners Inc does not currently pay a dividend.
To buy shares in Arch Biopartners Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arch Biopartners Inc are currently trading at C$1.33, giving the company a market capitalisation of £47.4m.
Here are the trading details for Arch Biopartners Inc:
Based on an overall assessment of its quality, value and momentum, Arch Biopartners Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Arch Biopartners Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arch Biopartners Inc. Over the past six months, the relative strength of its shares against the market has been -25.58%. At the current price of C$1.33, shares in Arch Biopartners Inc are trading at -4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Arch Biopartners Inc.
Arch Biopartners Inc's management team is headed by:
Here are the top five shareholders of Arch Biopartners Inc based on the size of their shareholding:
